Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $66.13 Consensus PT from Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have received an average rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $66.13.

JANX has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a research report on Monday. HC Wainwright restated a “buy” rating and issued a $63.00 price target on shares of Janux Therapeutics in a research note on Monday, August 19th. Stifel Nicolaus began coverage on Janux Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $70.00 price target for the company. Scotiabank dropped their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research note on Friday, August 9th. Finally, Wedbush restated an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th.

Insider Activity at Janux Therapeutics

In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the sale, the insider now owns 3,162,851 shares in the company, valued at approximately $132,839,742. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 268,578 shares of company stock worth $12,071,151. Company insiders own 35.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of JANX. Swiss National Bank increased its stake in Janux Therapeutics by 39.5% in the fourth quarter. Swiss National Bank now owns 31,800 shares of the company’s stock worth $341,000 after purchasing an additional 9,000 shares during the period. Janney Montgomery Scott LLC purchased a new stake in Janux Therapeutics in the fourth quarter worth $553,000. China Universal Asset Management Co. Ltd. increased its stake in Janux Therapeutics by 82.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,743 shares of the company’s stock worth $367,000 after purchasing an additional 4,400 shares during the period. Capstone Investment Advisors LLC purchased a new stake in Janux Therapeutics in the first quarter worth $1,969,000. Finally, Lester Murray Antman dba SimplyRich purchased a new stake in Janux Therapeutics in the first quarter worth $300,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Down 0.2 %

JANX stock opened at $49.89 on Thursday. Janux Therapeutics has a twelve month low of $5.65 and a twelve month high of $65.60. The stock has a market cap of $2.59 billion, a P/E ratio of -40.89 and a beta of 3.57. The business’s 50-day moving average price is $42.99 and its 200-day moving average price is $44.15.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.20. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The firm had revenue of $8.90 million for the quarter, compared to analysts’ expectations of $0.77 million. The firm’s revenue was up 709.1% on a year-over-year basis. On average, equities research analysts expect that Janux Therapeutics will post -1.18 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.